

Ref. No.: WOCK/SEC/SE/2021-22/102

8<sup>th</sup> October, 2021

**BSE Limited** 

Corporate Relations Department P J Towers, Dalal Street Mumbai - 400 001

**Scrip Code: 532300** 

National Stock Exchange of India Limited,

Exchange Plaza, Block G, Plot C 1, Bandra Kurla Complex, Bandra East, Mumbai 400051

NSE Symbol: WOCKPHARMA

Dear Sir/ Madam,

Sub: Confirmation/ Clarification on news items on Wockhardt Limited

Ref: (i) BSE letter no. L/SURV/ONL/RV/NK/ (2021-2022)/ 28 dated 8<sup>th</sup> October 2021

(ii) NSE letter no. NSE/CM/Surveillance/11199 dated 8<sup>th</sup> October 2021

This is with reference to your aforesaid letters/email dated 8<sup>th</sup> October 2021 advising us to provide clarification /confirmation on a news item appearing in certain Media/Publications pertaining to proposed stake sale by Wockhardt Limited.

In this regards, please find below our point wise reply to the clarification/confirmation sought by you:

1. Whether such negotiations were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order from the start of negotiations till date:-

The Company is in the process of evaluating/ negotiating **various** fund raising options, including by way of further issue of equity shares, as part of its normal course of business. The above negotiations are in its initial stage and, if found feasible, will be subject to further approval by the Board of Directors of the Company before finalisation. Therefore, the present news information detailing the deal/ parties to the deal are purely speculative in nature.

2. Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading? If so, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.:-

The Company is compliant with and is committed to fully comply with all regulatory requirements, including the requirements of regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 within the stipulated period, in the event of any development triggering such disclosure requirements. Since no definitive agreement or





arrangement have been entered into by the Company with any party, at present there is no information that can be announced by the Company to the Stock Exchanges in this regard.

## 3. The material impact of this article on the Company

Since the article is speculative in nature, there will be no material impact of this article on the Company.

The Company has always in the past submitted information, time to time, as required by the relevant statutes and is also committed to do so in future.

Thanking you and assuring you of our cooperation at all the time.

For Wockhardt Limited

Debashis Dey Company Secretary

Ranked # 1 in Healthcare

GREAT
Best
Companies
to Work for 2015
India